The cost-effectiveness ratios of statin therapy in older patients who have previously had myocardial infarction are reasonable
under a variety of assumptions about drug efficacy, drug cost, and rates of cardiac and cerebrovascular events. Pending results
of randomized, controlled trials of secondary prevention in patients in this age group, statin therapy seems to be as cost-effective
as many routinely accepted medical interventions in this setting.